Abstract Book of ESMO Breast Cancer 2024, Berlin, Germany, 15-17 May 2024Publication of this Abstract book is supported by the European Society for Medical Oncology May 2024 Previous vol/issue Next vol/issue Actions for selected articles
(2) E7386 is created through collaboration research between Eisai and PRISM BioLab Co., Ltd. (Headquarters: Kanagawa) (3) The presentation with TiP (Trial in Progress Submission) attached to the abstract number indicates that the study is in the intermediate stage, an...
Dr. Junmin Song:So for elderly patients, that part, first when he sent the abstract, the data was cut off until April. After we followed up until August, which was presented today, there was no difference for the...
Abstract Book of the Molecular Analysis for Precision Oncology Congress (MAP) 2024 London, UK, 16-18 October 2024Publication of this Abstract book is supported by the European Society for Medical Oncology October 2024 Previous vol/issue Next vol/issue ...
results of HLX07-NPC201 were accepted as a Late-breaking Abstract and were presented by Professor Li Zhang. Moreover, the results of HLX07-CSCC201 were first presented at ESMO Asia 2023, where its poster won the best poster award, and were presented with updated results at ESMO Asia 2024...
Abstract #585P, Poster, September 16 About LUMAKRAS®/LUMYKRAS® (sotorasib)LUMAKRAS received accelerated approval from the U.S. Food and Drug Administration (FDA) on May 28, 2021. The U.S. FDA completed its review of Amgen's supplemental New Drug Application (sNDA...
Only abstracts for whichno conclusive data are available at the time of the abstract submission deadline of9 January 2024will be considered for late-breaking status. The workmust nothave been previously published in any publication in a peer review setting or presented at a meeting of any other...
All accepted abstracts will be published online in the ESMO Gynae 2023 Abstract Book, a supplement toESMO Open. 注册费: In-person participation includes: Participation in the scientific and educational live sessions with the possibility to interact with the expert panel ...
KP, Bruno DS, Kitazono S, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced/metastatic NSCLC: initial results from the phase 1b TROPION-Lung04 study. Presented at: 2023 World Conference on Lung Cancer; September 10-12, 2023; Singapore. Abstract OA05.06. ...
Abstract:150P Title:Phase 1/2a trial of CD200R1 inhibitor 23ME-00610; exploratory analyses of tissue-based and genetic biomarkers Session Type:Poster Session – Biomarkers and Translational Research (agnostic) Date and Time:September 15, 9:00-17:00 Central European Summer...